KRAS inhibitor!

Article source: Pharmaceutical Guanlan

Jacos Pharmaceuticals recently announced that its research project, the KRAS G12C inhibitor JAB-21822, was approved for clinical use in China on May 27 following its recent clinical approval in the United States
.
According to the press release, Jacos Pharmaceuticals will start multi-center clinical trials for tumor patients with non-small cell lung cancer, colorectal cancer and other solid tumors in China and the United States, and plan to start patient enrollment in the second half of 2021

KRAS is one of the most frequently mutated oncogenes in human cancers.
In addition to directly promoting the proliferation and survival of tumor cells, its mutations can also affect the tumor microenvironment
.
The emergence of KRAS G12C inhibitors is an important breakthrough in the research field of targeting KRAS, a famous "non-drugable" target

Just today (May 29), the U.
S.
FDA announced an accelerated approval for the marketing of sotorasib developed by Amgen to treat non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations
.
This is the first anti-cancer therapy that targets any mutation in the KRAS gene, and it is also a milestone for scientists to break through the "undrugability" of KRAS

JAB-21822 is a class 1 small molecule anti-tumor drug independently developed by Jacos Pharmaceuticals.
It will be developed to treat patients with advanced solid tumors with KRAS G12C mutations
.
According to the press release, from preclinical studies, JAB-21822 has excellent oral bioavailability and systemic drug exposure, as well as good pharmacokinetic characteristics and tolerability

The press release pointed out that Jacos Pharmaceuticals is committed to overcoming non-drugable targets and has six projects around the RAS tumor signaling pathway, including the upstream SHP2 of KRAS
.
SHP2 is an important signal regulator of the RAS/MAPK pathway in cells.

Note: The original text has been deleted

Reference materials:

[1] GAX KRAS G12C inhibitor IND approved in China will start a Sino-US multi-center clinical trial.

[2] The clinical trial application for the new drug of GKRAS KRAS G12C inhibitor was approved in the United States.